Carborane-FAPI conjugate: A potential FAP-targeted boron agent with improved boron content

Appl Radiat Isot. 2024 Apr 23;209:111330. doi: 10.1016/j.apradiso.2024.111330. Online ahead of print.ABSTRACTBoron neutron capture therapy (BNCT) has received extensive attention as an advanced binary radiotherapy method. However, BNCT still faces poor selectivity of boron agent and is insufficient boron content in tumor tissues. To improve the tumor-targeted ability and boron content, this research aims to design, synthesize and preliminary evaluate a new borane agent Carborane-FAPI, which coupling the o-carborane to the compound skeleton of a mature fibroblast activating protein (FAP) inhibitor (FAPI). FAP is a tumor-associated antigen. FAP expressed lowly in normal organs and highly expressed in tumors, so it is a potential target for diagnosis and treatment. Boronophenylalanine (BPA) is the most widely investigated BNCT drug in present. Compared with BPA, the boron content of a single molecule is increased and drug targeting is enhanced. The results show that Carboaren-FAPI has low toxicity to normal cells, and selective enrichment in tumor tissues. It is a promising boron drug that has the potential to be used in BNCT.PMID:38657372 | DOI:10.1016/j.apradiso.2024.111330
Source: Applied Radiation and Isotopes - Category: Radiology Authors: Source Type: research
More News: Radiology | Toxicology